Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Helixis, a developer of nucleic acid analysis tools, has appointed Jay Flatley, CEO of Illumina, to its board of directors.
Subscribe to our email newsletter
Prior to joining Illumina, Mr Flatley was president and CEO of Molecular Dynamics, now part of GE Healthcare, and led that company’s initial public offering in 1993.
Mr Flatley holds a bachelor’s degree in economics from Claremont McKenna College and bachelor’s and master’s degrees from Stanford University.
Alex Dickinson, CEO of Helixis, said: “Jay is highly respected in the life science industry and has a comprehensive understanding of the market and customer segments that Helixis will serve with our unique instrument platforms. In particular he brings a strong background in operating management, which will be invaluable as we launch our first commercial product.”